Roche Receives EU Approval for Venclyxto (venetoclax) plus MabThera (rituximab) to Treat Adults with CLL

Shots:

• The approval is based on the results of P-III MURANO study assessing Venclexta + MabThera (six cycles) vs (bendamustine + MabThera) (BR) (six cycles) in 389 patients in ratio (1:1) with 1L r/r CLL for two years
• P-III MURANO study results: mPFS 83%; no. of events (32 vs 114); ORR (93.3% vs 67.7%); CR/CRi (26.8% vs 8.2%); MRD-negativity in peripheral blood, bone marrow (62.5%, 15.5% vs 13.3%,1.0%)
• Venclyxto is a novel inhibitor of B-cell lymphoma-2 (BCL-2) protein, developed by Roche & AbbVie and is currently approved in 50 countries

Click here to read full press release/ article | Ref: Roche | Image: Fortune